TY  - GEN
TI  - What are the optimal endpoints for FTLD clinical trials given the heterogeneity of clinical presentations?
AU  - Questions, Backfill Open
PY  - 2026
UR  - https://scidex.ai/artifact/open_question-a6aac6b9-7092-4a7c-b11c-2c9b60f2b56d
PB  - SciDEX
ER  -